{
    "clinical_study": {
        "@rank": "92266", 
        "arm_group": [
            {
                "arm_group_label": "PF-06444753", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PF-06444752", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intramuscular"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of different doses of\n      PF-06444753 and PF-06444752 in subjects with allergic rhinitis."
        }, 
        "brief_title": "A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, males or females of non-child bearing potential, who are between 18 and 55\n             years, inclusive,\n\n          -  Intermittent or persistent allergic rhinitis that is associated with perennial or\n             seasonal allergen reactivity at screening as determined by a positive specific IgE\n             level \u22651 KU/L to at least one of the following common allergens: dust mite\n             (Dermatophagoides farinae or Dermatophagoides pteronyssinus), cat, dog, mold\n             (Alternaria), Bermuda grass, common ragweed, oak, Timothy grass or elm.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic\n             disease that may compromise their ability to safely participate in the study.\n\n          -  Evidence or history of clinically significant pulmonary disease (including allergic\n             and non-allergic asthma, chronic obstructive pulmonary disease [COPD], cystic\n             fibrosis, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary\n             fibrosis, pulmonary hypertension, or others).\n\n          -  Evidence or history of clinically significant autoimmune disease (including\n             rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, or others)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "189", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723254", 
            "org_study_id": "B4901001"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-06444753", 
                "description": "Intramuscular, multiple dose", 
                "intervention_name": "IGE-1", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PF-06444752", 
                "description": "Intramuscular, multiple dose", 
                "intervention_name": "IGE-2", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Saline (0.9% sodium chloride)", 
                "intervention_name": "Saline", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccines", 
            "Phase 1", 
            "Allergic Rhinitis"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4901001&StudyName=A%20Study%20To%20Assess%20The%20Safety%20And%20Tolerability%20Of%20Different%20Doses%20Of%20PF-06444753%20And%20PF-06444752%20In%20Subjects%20With%20Allergic%20Rhinitis"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1Y 4G2"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4N 3C5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J1H 1Z1"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1V 4M6"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-IgE Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Frequency of local reactogenicity events", 
                "measure": "Local reactogenicity events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 14 days after dose"
            }, 
            {
                "description": "Frequency of systemic reactogenicity events", 
                "measure": "Systemic reactogenicity events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 14 days after dose"
            }, 
            {
                "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.  An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.", 
                "measure": "Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 336"
            }, 
            {
                "description": "blood chemistry, hematology, coagulation, and urinalysis", 
                "measure": "Number of Participants with abnormal safety laboratory findings", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 336"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723254"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Antibody titers against IgE", 
            "measure": "Antibody titers against IgE", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to Day 336"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}